A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

BACKGROUND: Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of chemotherapy-induced nausea and vomiting (CINV). NEPA is a new oral fixed-dose combination of 300 mg netupitant, a highly selective...

Descripción completa

Detalles Bibliográficos
Autores principales: Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071754/
https://www.ncbi.nlm.nih.gov/pubmed/24603643
http://dx.doi.org/10.1093/annonc/mdu101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071754/
https://www.ncbi.nlm.nih.gov/pubmed/24603643
http://dx.doi.org/10.1093/annonc/mdu101

Ejemplares similares